Clinical Trial Update: GLASSIA Infusion Rate Study [Phase 4]

View source ↗

Summary

Phase 4 trial update on GLASSIA infusion rate study; completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency

Drugs mentioned

• Glassia (alpha-1 proteinase inhibitor)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Alpha1-antitrypsin Deficiency, Healthy Volunteers | Phase 4 | Status: COMPLETED | Results posted: 2014-05-29